Karyopharm Therapeutics Inc.(KPTI)- NASDAQ
  • Today, 12:47 PM
    | Today, 12:47 PM
  • Today, 11:01 AM
    | Today, 11:01 AM | 1 Comment
  • Today, 10:48 AM
    • Thinly traded micro cap Karyopharm Therapeutics (KPTI +22.2%) heads north on more than a 4x surge in volume. No particular news accounts for the high volume action although investors may be starting to build positions ahead of the release of data from a Phase 2 clinical trial, STORM, assessing lead product candidate selinexor in treatment-resistant multiple myeloma. Top-line results should be available in September.
    • Selinexor is a SINE (Selective Inhibitor of Nuclear Export) compound. It binds to and inhibits the nuclear export protein XPO1 which leads to the accumulation of tumor suppressor proteins in the cell nucleus which amplifies tumor suppression. It is also under development for the treatment of liposarcoma, diffuse large B-cell lymphoma and acute myeloid leukemia.
    • Today, Jefferies upgraded to stock to Buy from Hold with a $12 (37% upside) price target based on the expectation of positive STORM results.
    | Today, 10:48 AM
  • Fri, Aug. 19, 8:01 AM
    • Arrowhead Pharmaceuticals (NASDAQ:ARWR) initiated with Buy rating and $15 (112% upside) price target by Cantor Fitzgerald.
    • Karyopharm Therapeutics (NASDAQ:KPTI) initiated with Buy rating and $15 (92% upside) price target by H.C. Wainwright.
    • Mediwound Ltd. (NASDAQ:MDWD) initiated with Outperform rating and $14 (75% upside) price target by Wells Fargo.
    • SCYNEXIS (NASDAQ:SCYX) initiated with Buy rating and $15 (436% upside) price target by Guggenheim Securities.
    • Patheon NV (Pending:PTHN) initiated with Neutral rating and $30 (7% upside) price target by Credit Suisse. Initiated with Buy rating and $32 (14% upside) price target by Jefferies. Initiated with Overweight rating and $31 (11% upside) price target by Morgan Stanley.
    • GlycoMimetics (NASDAQ:GLYC) initiated with Outperform rating by Cowen and Company. Initiated with Outperform rating and $32.50 (306% upside) price target by Raymond James.
    • Audentes Therapeutics (Pending:BOLD) initiated with an Outperform rating by Cowen and Company. Initiated with Outperform rating and $20 (33% upside) price target by Wedbush.
    • Mallinckrodt (NYSE:MNK) initiated with Buy rating and $95 (19% upside) price target by Stifel Nicolaus.
    • TESARO (NASDAQ:TSRO) initiated with Outperform rating and $122 (28% upside) price target by RBC Capital.
    | Fri, Aug. 19, 8:01 AM | 1 Comment
  • Thu, Aug. 18, 9:13 AM
    • Thinly traded micro cap Karyopharm Therapeutics (NASDAQ:KPTI) is up 7% premarket, albeit on only 5,650 shares. H.C. Wainwright initiated coverage with a Buy (what else) recommendation and $15 (100% upside) price target.
    | Thu, Aug. 18, 9:13 AM
  • Thu, Aug. 4, 7:33 AM
    • Karyopharm Therapeutics (NASDAQ:KPTI): Q2 EPS of -$0.84 misses by $0.08.
    • Revenue of $0.06M (-60.0% Y/Y) beats by $0.02M.
    • Press Release
    | Thu, Aug. 4, 7:33 AM
  • Fri, Jul. 1, 10:13 AM
    • Aldyra Therapeutics (NASDAQ:ALDX) initiated with Buy rating and $16 (158% upside) price target by Stifel Nicolaus.
    • Shire plc (NASDAQ:SHPG) re-initiated with Buy rating and 6300p (36% upside) price target by Goldman Sachs.
    • Karyopharm Therapeutics (NASDAQ:KPTI) initiated with Outperform rating and $16 (129% upside) price by Baird.
    • Ultragenyx (NASDAQ:RARE) initiated with Buy rating and $72 (41% upside) price target by Bank of America.
    • NantHealth (NASDAQ:NH) initiated with Buy rating and $17 (36% upside) price target by Canaccord Genuity. First Analysis rates it Overweight with an $18 (44% upside) price target. Cowen and Company rates it Outperform with a $19 (52% upside) price target.
    • Clearside Biomedical (Pending:CLSD) initiated with Buy rating and $13 (84% upside) price target by Stifel Nicolaus. Cowen & Company rates it Outperform. Wedbush rates it Outperform with $28 (296% upside) price target.
    • GW Pharmaceuticals (NASDAQ:GWPH) initiated with Sell rating and $40 (57% downside risk) price target by Janney Capital.
    | Fri, Jul. 1, 10:13 AM | 3 Comments
  • Wed, Jun. 22, 8:38 AM
    • Karyopharm Therapeutics (NASDAQ:KPTIannounces the dosing of the first patient in a Phase 1 clinical trial evaluating KPT-9274 in patients with advanced solid malignancies (including sarcoma, colon and lung cancer) or Non-Hodgkin's Lymphoma (NHL) whose disease has relapsed after standard treatment.
    • This first trial will enroll up to 175 patients.  The primary endpoints are to determine the recommended Phase 2 dose and the maximum tolerated dose of KPT-9274 administered alone and with extended release niacin, and to evaluate safety and tolerability.  The key secondary endpoint is to assess anti-tumor activity in patients predicted to be more sensitive to PAK4/NAMPT inhibition, including those with NAPRT-deficient tumors and tumors harboring IDH1 mutations.
    • According to ClinicalTrials.gov, the primary endpoint is overall response rate. The estimated final data collection date for the primary outcome measure is May 2017. The estimated study completion date is December 2017.
    • Small molecule KPT-9274 inhibits two enzymes, p21-activated kinase 4 (PAK4) and nicotinamide phosphoribosyltransferase (NAMPT). Co-inhibition of both targets is believed to fight cancer through the suppression of beta-catenin by blocking PAK4, leading to immune cell activation and restriction of tumor growth, energy depletion via NAMPT inhibition, blockade of DNA repair, cell cycle arrest and ultimately apoptosis (cell death).
    | Wed, Jun. 22, 8:38 AM
  • Fri, May 27, 4:56 PM
    • Globus Medical (NYSE:GMED) initiated with Equal Weight Rating and $26 (8% upside) price target by Barclays.
    • TG Therapeutics (NASDAQ:TGTX) initiated with Buy rating $18 (133% upside) price target by SunTrust Robinson Humphrey.
    • Karyopharm Therapeutics (NASDAQ:KPTI) initiated with Outperform rating and $13 (35% upside) price target by Raymond James.
    • SAGE Therapeutics (NASDAQ:SAGE) initiated with Sell rating and $18 (43% downside risk) price target by Chardan Capital.
    • Viking Therapeutics (NASDAQ:VKTX) initiated with Buy rating with a $5 (285% upside) price target by Maxim Group.
    • Fibrocell Science (NASDAQ:FCSC) resumed with Buy rating and $7 (229% upside) price target by Roth Capital Partners.
    • Asterias Biotherapeutics (NYSEMKT:AST) initiated with Buy rating and $5.50 (61% upside) price target by Chardan Capital.
    • Quorum Health (NYSE:QHC) initiated with Market Perform rating and $14 (6% upside) price target by Avondale Partners.
    • Radius Health (NASDAQ:RDUS) initiated with Buy rating and $55 (57% upside) price target by H.C. Wainwright.
    • Johnson & Johnson (NYSE:JNJ) initiated with Sell rating and $94 (17% downside risk) price target by Standpoint Research.
    • NuVasive (NASDAQ:NUVA) upgraded to Overweight from Equal Weight by Barclays. Price target raised to $63 (15% upside) from $58.
    • Zimmer Biomet Holdings (NYSE:ZBH) upgraded to Buy from Hold with a $125 (2% upside) price target by Argus Research.
    • Relypsa (NASDAQ:RLYP) upgraded to Equal Weight from Underweight with a $9 (50% downside risk) price target by Morgan Stanley. To be adjusted after ZS-9 rejection.
    • Ionis Pharmaceuticals (NASDAQ:IONS) downgraded to Market Perform from Outperform by BMO Capital Markets. Price target lowered to $26 (18% upside) from $55.
    • Patterson Companies (NASDAQ:PDCO) downgraded to Hold from Buy by Evercore ISI. Price target lowered to $48.50 (0% upside) from $49.50.
    • United Therapeutics (NASDAQ:UTHR) downgraded to Sell from Hold with a $114 (3% downside risk) price target by Argus Research.
    • Boston Scientific (NYSE:BSX) downgraded to Neutral from Buy with a $24.20 (7% upside) price target by BTIG Research.
    • Neovasc (NASDAQ:NVCN) downgraded to Neutral from Buy by Ladenburg Thalmann. Price target removed.
    | Fri, May 27, 4:56 PM | 17 Comments
  • Mon, May 9, 7:32 AM
    • Karyopharm Therapeutics (NASDAQ:KPTI): Q1 EPS of -$0.75 misses by $0.01.
    • Press Release
    | Mon, May 9, 7:32 AM
  • Tue, May 3, 5:37 PM
    | Tue, May 3, 5:37 PM
  • Mon, Mar. 14, 7:32 AM
    • Karyopharm Therapeutics (NASDAQ:KPTI): Q4 EPS of -$0.81 beats by $0.01.
    • Revenue of $0.03M (+50.0% Y/Y) beats by $0.02M.
    • Press Release
    | Mon, Mar. 14, 7:32 AM
  • Thu, Jan. 14, 7:41 AM
    • Karyopharm (NASDAQ:KPTI) commences a Phase 2/3 clinical trial, SEAL, assessing oral selinexor in patients with advanced liposarcoma, a rare cancer that originates in fat cells in deep soft tissue.
    • SEAL is a multicenter, double-blind, placebo-controlled study that will randomize 50 patients to receive either 60 mg of selinexor or placebo twice weekly per six-week cycle until cancer progression or intolerability. The primary endpoint is progression-free survival. Top-line results from the Phase 2 portion are expected in early 2017.
    • The data supporting the initiation of the study was generated in a Phase 1b trial that showed 14 of 18 patients with liposarcoma experienced a longer period of stable disease compared to their most recent therapy. Six achieved stable disease for greater than four months. The survival rate for recurrent and high-grade forms of liposarcoma is less than 5%.
    • Selinexor is a SINE (Selective Inhibitor of Nuclear Export) compound. It binds to and inhibits the nuclear export protein XPO1 which leads to the accumulation of tumor suppressor proteins in the cell nucleus which amplifies tumor suppression. It is also under development for the treatment of multiple myeloma, diffuse large B-cell lymphoma and acute myeloid leukemia.
    | Thu, Jan. 14, 7:41 AM
  • Wed, Jan. 6, 12:45 PM
    | Wed, Jan. 6, 12:45 PM | 1 Comment
  • Nov. 10, 2015, 5:40 PM
    | Nov. 10, 2015, 5:40 PM | 2 Comments
  • Nov. 9, 2015, 7:32 AM
    • Karyopharm Therapeutics (NASDAQ:KPTI): Q3 EPS of -$0.85 beats by $0.02.
    • Revenue of $0.08M (+300.0% Y/Y) beats by $0.01M.
    | Nov. 9, 2015, 7:32 AM
Company Description
Karyopharm Therapeutics, Inc. is a clinical-stage pharmaceutical company. It is focused on the discovery and development of novel first-in-class drugs directed against nuclear transport targets for the treatment of cancer and other major diseases. Its selective inhibitors of nuclear export... More
Sector: Healthcare
Industry: Drug Manufacturers - Major
Country: United States